After 12 months of use, 58% of patients achieved a BMI reduction 5%, 35% achieved a BMI reduction 10%, and 17% achieved a BMI reduction 15%
Track symptoms A simple food journal helps connect the dots
According to the Obesity Medicine Association: Since semaglutides are relatively new medications, long-term risks of semaglutides are not known
Souza, D
This is fundamentally different from semaglutide dosing
Research by Dhillo, Jayasena, and Comninos at Imperial College London has established that kisspeptin signaling is dysregulated in PCOS, and that administering exogenous kisspeptin can trigger coordinated LH surges in women with the condition.[8] A phase 2 trial demonstrated that subcutaneous kisspeptin administration successfully triggered ovulation in a proportion of women with PCOS who had not responded to conventional ovulation induction, including clomiphene citrate.[9] This is a genuinely novel therapeutic signal kisspeptin addresses a mechanism that metformin, combined oral contraceptives, and clomiphene do not touch
